NASDAQ:BRNS Barinthus Biotherapeutics (BRNS) Stock Price, News & Analysis $1.36 -0.10 (-6.85%) Closing price 10/10/2025 03:59 PM EasternExtended Trading$1.30 -0.06 (-4.41%) As of 10/10/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Barinthus Biotherapeutics Stock (NASDAQ:BRNS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BRNS alerts:Sign Up Key Stats Today's Range$1.36▼$1.5150-Day Range$1.05▼$1.5852-Week Range$0.64▼$2.92Volume45,471 shsAverage Volume260,508 shsMarket Capitalization$55.38 millionP/E RatioN/ADividend YieldN/APrice Target$3.00Consensus RatingHold Company Overview Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom. Read More Barinthus Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreBRNS MarketRank™: Barinthus Biotherapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 589th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingBarinthus Biotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialBarinthus Biotherapeutics has a consensus price target of $3.00, representing about 120.6% upside from its current price of $1.36.Amount of Analyst CoverageBarinthus Biotherapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Barinthus Biotherapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Barinthus Biotherapeutics are expected to grow in the coming year, from ($1.38) to ($1.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Barinthus Biotherapeutics is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Barinthus Biotherapeutics is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBarinthus Biotherapeutics has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Barinthus Biotherapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.22% of the float of Barinthus Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverBarinthus Biotherapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Barinthus Biotherapeutics has recently increased by 498.51%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBarinthus Biotherapeutics does not currently pay a dividend.Dividend GrowthBarinthus Biotherapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.22% of the float of Barinthus Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverBarinthus Biotherapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Barinthus Biotherapeutics has recently increased by 498.51%, indicating that investor sentiment is decreasing significantly. News and Social Media2.6 / 5News Sentiment0.63 News SentimentBarinthus Biotherapeutics has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Barinthus Biotherapeutics this week, compared to 1 article on an average week.Search Interest5 people have searched for BRNS on MarketBeat in the last 30 days. MarketBeat FollowsOnly 2 people have added Barinthus Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Barinthus Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders10.70% of the stock of Barinthus Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 25.20% of the stock of Barinthus Biotherapeutics is held by institutions.Read more about Barinthus Biotherapeutics' insider trading history. Receive BRNS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Barinthus Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BRNS Stock News Headlines$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Barinthus Biotherapeutics plc (NASDAQ: BRNS)October 7, 2025 | globenewswire.comBARINTHUS BIOTHERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNSOctober 3, 2025 | businesswire.comINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.October 11 at 2:00 AM | Traders Agency (Ad)Barinthus Biotherapeutics Announces Merger with Clywedog TherapeuticsOctober 2, 2025 | msn.comBarinthus Biotherapeutics (NASDAQ:BRNS) Shares Down 15.5% - Here's What HappenedOctober 1, 2025 | americanbankingnews.comBarinthus Biotherapeutics To Merge With Privately-Held Clywedog TherapeuticsSeptember 30, 2025 | msn.comBRNS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Barinthus Biotherapeutics plc Is Fair to ShareholdersSeptember 30, 2025 | businesswire.comBarinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune DiseasesSeptember 30, 2025 | globenewswire.comSee More Headlines BRNS Stock Analysis - Frequently Asked Questions How have BRNS shares performed this year? Barinthus Biotherapeutics' stock was trading at $1.2080 on January 1st, 2025. Since then, BRNS stock has increased by 12.6% and is now trading at $1.36. How were Barinthus Biotherapeutics' earnings last quarter? Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) issued its quarterly earnings data on Thursday, August, 7th. The company reported ($0.52) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by $0.23. How do I buy shares of Barinthus Biotherapeutics? Shares of BRNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Barinthus Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Barinthus Biotherapeutics investors own include PayPal (PYPL), Avino Silver & Gold Mines (ASM), Cogent Communications (CCOI), Datadog (DDOG), Intuitive Surgical (ISRG), nCino (NCNO) and Construction Partners (ROAD). Company Calendar Last Earnings8/07/2025Today10/11/2025Next Earnings (Estimated)11/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BRNS Previous SymbolNASDAQ:BRNS CIK1828185 Webwww.barinthusbio.com Phone44-1865-818-808FaxN/AEmployees107Year FoundedN/APrice Target and Rating Average Price Target for Barinthus Biotherapeutics$3.00 High Price Target$3.00 Low Price Target$3.00 Potential Upside/Downside+120.6%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$61.07 million Net MarginsN/A Pretax Margin-464.63% Return on Equity-54.70% Return on Assets-44.75% Debt Debt-to-Equity RatioN/A Current Ratio7.89 Quick Ratio7.89 Sales & Book Value Annual Sales$14.97 million Price / Sales3.70 Cash FlowN/A Price / Cash FlowN/A Book Value$3.23 per share Price / Book0.42Miscellaneous Outstanding Shares40,718,000Free Float36,361,000Market Cap$55.38 million OptionableN/A Beta-0.71 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:BRNS) was last updated on 10/11/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Barinthus Biotherapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Barinthus Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.